Cross-border prescribing: what insurers need to know about the NDE

Managing interstate medication use and understanding the National Database Entry (NDE) in your claims assessment.

Published 3 April 2026

The problem: cross-border prescribing gaps in insurance claims

State-based real-time prescription monitoring systems (RTPM) like QScript, ScriptCheckSA, ScriptCheckWA, TasScript, NTScript, and CanberraScript work well within their respective states. But if your claimant has accessed treatment across state borders, you have a medication data gap. A claimant who files a workers' compensation claim in Queensland but received treatment in NSW, who works near a state border and sees doctors in multiple states, or who relocates during their claim creates a situation where no single state RTPM system captures their complete medication history.

Understanding the National Database Entry (NDE)

To address cross-border prescribing gaps, Australia has the National Database Entry (NDE), a shared system that allows authorised practitioners to access prescription data from multiple states. The NDE integrates data from state RTPM systems and provides a national view of controlled substance prescribing across Australia. This is particularly valuable for tracking opioid, benzodiazepine, and other controlled substance use across state borders.

What the NDE captures

The NDE provides access to controlled substance prescribing data from all Australian states and territories. If your claimant has obtained opioid analgesics, benzodiazepines, or other controlled substances in multiple states, the NDE will show that complete history. This is critical for identifying doctor shopping or other problematic prescribing patterns that cross state borders.

What the NDE doesn't capture

The NDE focuses on controlled substances. Non-controlled prescribed medicines may not be captured in the NDE, depending on state-specific data-sharing arrangements. Private prescriptions obtained overseas are not captured. Over-the-counter medicines and supplements are not included. This means the NDE provides targeted coverage of high-risk medicines but not a complete medication picture.

When to refer for cross-border medication assessment

You should consider requesting NDE-based assessment when your claimant has any of these characteristics:

• Works or lives near a state border and may have accessed treatment in multiple states
• Relocated during their claim period
• Reports treatment from practitioners in different states
• Has family or personal reasons to travel between states regularly
• Is claiming for medicines that are commonly doctor-shopped (opioids, benzodiazepines, stimulants)
• Shows high-dose prescribing patterns that might indicate doctor shopping
• Has insurance coverage spanning multiple states (CTP claims, life insurance, etc.)

How cross-border prescribing reveals itself in claims

Cross-border medication use shows up in several ways:

Medication gaps and overlaps

If you see pharmacy records from your claimant's home state but not complete evidence of all their medications, there may be prescriptions filled in other states. These gaps can hide dangerous drug interactions or uncoordinated prescribing.

Inconsistent dosing history

If treating doctors report certain medication doses but pharmacy records show different quantities being dispensed, your claimant may be accessing additional prescriptions in other states.

Unexplained treatment complexity

If your claimant is on a complicated medication regimen that seems inconsistent with their injury or treating practitioner information, cross-border prescribing may be the explanation. Multiple doctors in different states prescribing without coordination can result in a complex medication profile.

Managing cross-border prescribing in your claim

When you identify or suspect cross-border prescribing, your options include:

Request NDE-based medication review

Refer your claimant for NDE-based medication assessment through a specialist provider like IMM. This will capture controlled substance prescribing across all states and reveal the complete national picture of your claimant's medication use.

Request treatment records from out-of-state practitioners

Directly request medical records and prescribing information from treating practitioners in other states. This is more time-consuming than NDE review but may provide additional clinical context.

Conduct specialist pharmacist interview with your claimant

During a medication review appointment, the pharmacist can directly ask your claimant about out-of-state treatment and medication access. Combined with NDE data, this provides comprehensive insight into their actual medication history.

Cross-border prescribing and doctor shopping

Cross-border prescribing can be benign (legitimate treatment access across state borders) or problematic (doctor shopping for controlled substances across states to avoid detection). The NDE helps distinguish between these scenarios. If NDE data shows your claimant is obtaining opioids from multiple prescribers in different states without coordination, this is a significant red flag requiring immediate intervention.

Regulatory and practical considerations

Prescribers are increasingly expected to check both state RTPM systems and the NDE before prescribing controlled substances. If prescribers in the various states your claimant is being treated in are not checking the NDE, there's a coordination gap. A specialist medication review can flag this and make recommendations to treating teams.

The bottom line: closing cross-border gaps

State RTPM systems are excellent tools, but they have a limitation: they only show what happened within their state. If your claimant has accessed treatment across state borders, you need NDE-based assessment to complete the medication picture. This is particularly important for high-risk claims where medication coordination and safety are critical. Don't let cross-border prescribing create blind spots in your medication risk assessment.